EtiraRx develops targeted therapies for therapy-resistant metastatic breast cancer, utilizing advanced mechanisms that adapt to the evolving mutations of cancer cells. This approach aims to improve patient outcomes by effectively attacking cancer in its various forms, providing renewed hope for those facing aggressive cancers.
Funding
$4.8M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Metastatic breast cancer, particularly therapy-resistant forms, poses a significant challenge due to the cancer cells' ability to mutate and adapt, leading to treatment failure and poor patient outcomes. Current therapies often struggle to keep pace with the evolving nature of these aggressive cancers.
Solution
EtiraRx is developing targeted cancer therapies designed to overcome resistance in metastatic breast cancer by adapting to the evolving mutations of cancer cells. Their approach aims to provide a more effective treatment option that can attack cancer in its various forms, even as it mutates. By focusing on mechanisms that can outsmart the cancer's ability to adapt, EtiraRx seeks to improve outcomes for patients facing aggressive metastatic cancers. The company's goal is to create "smarter medicine" that can disrupt cancer's ability to thrive and ultimately transform it into a treatable disease.
Target Audience
The primary target audience is patients with therapy-resistant metastatic breast cancer and the oncologists who treat them.
Features
- Targeted therapies designed to address therapy-resistant metastatic breast cancer.
- Mechanisms that adapt to the evolving mutations of cancer cells.
- Focus on destroying cancer from the inside out.